Business Context and Reporting Period
This Form 8-K was filed by Save Foods, Inc., not Nexentis Technologies Inc., on September 24, 2020, reporting financing transactions entered into on September 23–24, 2020. The company’s principal office was in Tel Aviv, Israel.
Key Financial and Capitalization Matters
- The company entered into convertible loan agreements with aggregate principal of $125,000.
- The notes bear interest at 5% annually and mature on the earlier of the third anniversary of each agreement or a defined deemed liquidation event.
- Lenders may convert some or all of the notes into common stock at $1.09 per share before a mandatory conversion event.
- Principal is scheduled to be repaid in four semiannual installments beginning one year after each closing; accrued interest is scheduled to be paid in two semiannual installments beginning one year after the first principal payment.
- Each lender received piggyback registration rights for shares issuable upon conversion.
- Separately, the company sold Medigus Ltd. 91,743 units for $100,000, or $1.09 per unit. Each unit included one common share and one warrant exercisable for one common share at $1.20 per share.
- The transaction issued 91,743 common shares and warrants to purchase 91,743 additional shares.
- Medigus may make an additional investment of up to $25,000 following initiation of a proof-of-concept procedure. The contemplated issuance is 22,935 additional units with the same terms.
Material Changes Versus the Prior Comparable Period
The filing text does not provide comparative financial statements or prior-period operating results. It reports new debt financing, equity issuance, and potential additional equity-linked securities, which may increase the company’s liquidity but also create future repayment obligations and potential dilution.
Guidance, Outlook, Risks, and Unusual Items
- The additional Medigus investment is contingent on initiation of a proof-of-concept test concerning the effectiveness and residual effects of the company’s sanitizers against different pathogens.
- Conversion of the notes and exercise of the warrants could materially dilute existing shareholders.
- The company must repay the convertible notes and pay interest according to the stated schedules unless conversion or another defined event changes the outcome.
- The securities were issued or are to be issued in reliance on exemptions from registration under Section 4(a)(2) and/or Regulation S of the Securities Act.
- The filing provides no revenue, profit, cash-flow, margin, total debt, cash balance, liquidity runway, or formal business guidance figures.
Facts Investors Should Verify
- Confirm that the filing belongs to Save Foods, Inc.; the supplied request identifies Nexentis Technologies Inc.
- Review subsequent filings for the closing status and outstanding balance of the $125,000 convertible notes.
- Determine whether any notes converted, and quantify the resulting share issuance and dilution.
- Verify whether Medigus made the contemplated additional investment of up to $25,000 and whether the 22,935 additional units were issued.
- Review later filings for warrant exercises, registration of resale shares, repayment activity, and the results of the proof-of-concept procedure.